利培酮并帕罗西汀治疗有精神病性症状难治性抑郁症对照研究  

A control study between paroxetine monotherapy and paroxetine combined with risperidone for the treatment of refractory depression with psychotic symptoms

作　　者：鞠红珍 盖永新 刘晓玲[3] 于婷 梁红蕾 王深化 赵学庆 于晟培 

机构地区：[1]山东省烟台市心理康复医院,265200 [2]山东省烟台市莱州荣军医院 [3]山东省烟台市莱阳中心医院

出　　处：《精神医学杂志》2012年第5期371-373,共3页Journal of Psychiatry

摘　　要：目的评估利培酮合并帕罗西汀治疗有精神病性症状难治性抑郁症的疗效和安全性。方法将符合标准的有精神病性症状难治性抑郁症患者100例随机分为利培酮合并帕罗西汀组(研究组)和单用帕罗西汀组(对照组),应用汉密尔顿抑郁量表(HAMD)及副反应量表(TESS),在治疗前、治疗后2、4、6、12周末分别评定其疗效及安全性。结果研究组疗效优于对照组,其锥体外系副反应、体重增加也较对照组多见。结论利培酮对有精神病性症状难治性抑郁症有肯定的增效作用,值得在临床推广应用。Objective To evaluate the efficacy and safety of paroxetine combined with risperidone in the treatment of refractory depression with psychotic symptoms. Methods 100 patients were randomized into study group （50 cases） treated with paroxetine combined with risperidone and control group （50 cases） treated with paroxetine monotherapy for 12 weeks. Hamilton Depression Scale （HAMD） and Treatment Emergent Symptom Scale （TESS） were used to assess the efficacy and side effects respectively at the baseline and at the 2nd, 4th, 6th, 12th weekend of the treatment. Results Efficacy of study group was significantly better than that in control group. The prevalence of extrapyramidal side effect （EPS） and weight gain in study group were higher than those in control group. Conclusion Risperidone can play a synergistic action in the treatment of refractory depression with psychotic symptoms.

关 键 词：利培酮 帕罗西汀 精神病性 难治性抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]